Trial · NCT07895394
Immunogenicity and Safety of Respiratory Syncytial Virus Vaccine in Lung Transplant Recipients
NCT07895394, Phase 4, Recruiting, Seoul National University Hospital
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Immunogenicity and Safety of Respiratory Syncytial Virus Vaccine in Lung Transplant Recipients. Trials, record NCT07895394. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07895394
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Immunogenicity and Safety of Respiratory Syncytial Virus Vaccine in Lung Transplant Recipients
- NCT number
- NCT07895394
- Status
- Recruiting
- Phases
- Phase 4
- Enrollment
- 80 participants, estimated
- Lead sponsor
- Seoul National University Hospital
- Conditions
- Vaccination, Respiratory Syncytial Virus (RSV), Lung Transplant Recipient
- Interventions
- RSVPreF3 vaccination
- First posted
- 2026-10-26
- Last updated
- 2026-10-26
Source ClinicalTrials.gov
Registered outcomes13
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Humoral immune response (neutralizing antibody) | 1 month after vaccination | Geometric mean fold rise (GMFR) in RSV-A neutralizing antibody titers from pre-vaccination to 1 month after vaccination, compared between lung transplant recipients and immunocompetent adults. |
| Secondary | Humoral immune response (neutralizing antibody) | Prevaccination, 1 month and 12 months after vaccination | Geometric mean titers (GMTs) in RSV-A neutralizing antibody titers |
| Secondary | Humoral immune response (neutralizing antibody) | Prevaccination, 1 month and 12 months after vaccination | Geometric mean titers (GMTs) in RSV-B neutralizing antibody titers |
| Secondary | Humoral immune response (neutralizing antibody) | 1 month, 12 months after vaccination | Geometric mean fold rises (GMFRs) in RSV-A neutralizing antibody titers from pre-vaccination levels. |
| Secondary | Humoral immune response (neutralizing antibody) | 1 month, 12 months after vaccination | Geometric mean fold rises (GMFRs) in RSV-B neutralizing antibody titers from pre-vaccination levels. |
| Secondary | Humoral immune response (RSV specific antibody) | Prevaccination, 1 month and 12 months after vaccination | Geometric mean concentrations (GMCs) in RSVPreF3-specific IgG |
| Secondary | Humoral immune response (RSV specific antibody) | Prevaccination, 1 month and 12 months after vaccination | Geometric mean concentrations (GMCs) in pan-RSV-specific IgG |
| Secondary | Humoral immune response (RSV specific antibody) | 1 month, 12 months after vaccination | Geometric mean fold rises (GMFRs) in RSVPreF3-specific IgG from pre-vaccination levels. |
| Secondary | Humoral immune response (RSV specific antibody) | 1 month, 12 months after vaccination | Geometric mean fold rises (GMFRs) in pan-RSV-specific IgG from pre-vaccination levels. |
| Secondary | Humoral immune response (serologic response rate) | 1 month, 12 months after vaccination | Proportion of participants with a ≥4-fold increase in antibody levels from pre-vaccination levels |
1 to 10 of 13Source ClinicalTrials.gov
See all 13 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers15
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07895394
GET https://conductscience.org/api/trials/v1/NCT07895394/registered